Theravance Biopharma Inc
TBPH
Get informed when a big investor buys or sells
+ FollowMarket Cap$881.6M
Close$
$10.75
36.7% downside
Current Fair Value
36.7% downsideOvervalued by 36.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $881.60 Million |
|---|---|
| Enterprise Value | $700.40 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $2.1 |
| Beta | 0.17 |
| Outstanding Shares | 51,667,000 |
Return
| Return on Equity | 18.57% |
|---|---|
| Return on Assets | 11.45% |
| Return on Invested Capital | -0.01% |
Valuation & Multiples
| P/E Ratio | 15.99 |
|---|---|
| PEG | -14.44 |
| Price to Sales | 8.5 |
| Price to Book Ratio | 3.4 |
| Enterprise Value to Revenue | 6.71 |
| Enterprise Value to EBIT | -10943.78 |
| Enterprise Value to Net Income | 13 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.13 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$0.07
Average shareholder expectationRevenue Estimate
$22.49 M
Average shareholder expectationNext Earnings Call
Expected Date
November 10, 2026
EPS Estimate
$0.24
Average shareholder expectationRevenue Estimate
$21.95 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 4.6573▼ 726.17% |
|---|---|
| Total Calls | 14,300▼ 71.05% |
| Total Puts | 66,600▼ 88.69% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 95.47%▼ 2.23% |
|---|---|
| Total Invested | $860.34M▲ 5.81% |
| Investors Holding | 184▲ 5.00% |
ESG Score
No data
About Theravance Biopharma Inc
CEO: Rick Winningham